The matrix vesicle cargo miR-125b accumulates in the bone matrix, inhibiting bone resorption in mice

Minamizaki, Tomoko; Nakao, Yuko; Irie, Yasumasa; Ahmed, Faisal; Itoh, Shota; Sarmin, Nushrat; Yoshioka, Hirotaka; Nobukiyo, Asako; Fujimoto, Chise; Niida, Shumpei; Sotomaru, Yusuke; Tanimoto, Kotaro; Kozai, Katsuyuki; Sugiyama, Toshie; Bonnelye, Edith; Takei, Yuichiro; Yoshiko, Yuji

doi:10.1038/s42003-020-0754-2

Download PDF

Article
Open access
Published: 16 January 2020

The matrix vesicle cargo miR-125b accumulates in the bone matrix, inhibiting bone resorption in mice

Tomoko Minamizaki¹,
Yuko Nakao^1,2,
Yasumasa Irie^1,3,
Faisal Ahmed¹,
Shota Itoh^1,2,
Nushrat Sarmin¹,
Hirotaka Yoshioka ORCID: orcid.org/0000-0002-0948-1416¹^nAff8,
Asako Nobukiyo⁴,
Chise Fujimoto¹,
Shumpei Niida⁵,
Yusuke Sotomaru⁴,
Kotaro Tanimoto²,
Katsuyuki Kozai³,
Toshie Sugiyama⁶,
Edith Bonnelye⁷,
Yuichiro Takei ORCID: orcid.org/0000-0003-3760-0686¹^nAff9 &
…
Yuji Yoshiko¹

Communications Biology volume 3, Article number: 30 (2020) Cite this article

3184 Accesses
3 Altmetric
Metrics details

Subjects

Abstract

Communication between osteoblasts and osteoclasts plays a key role in bone metabolism. We describe here an unexpected role for matrix vesicles (MVs), which bud from bone-forming osteoblasts and have a well-established role in initiation of bone mineralization, in osteoclastogenesis. We show that the MV cargo miR-125b accumulates in the bone matrix, with increased accumulation in transgenic (Tg) mice overexpressing miR-125b in osteoblasts. Bone formation and osteoblasts in Tg mice are normal, but the number of bone-resorbing osteoclasts is reduced, leading to higher trabecular bone mass. miR-125b in the bone matrix targets and degrades Prdm1, a transcriptional repressor of anti-osteoclastogenic factors, in osteoclast precursors. Overexpressing miR-125b in osteoblasts abrogates bone loss in different mouse models. Our results show that the MV cargo miR-125b is a regulatory element of osteoblast-osteoclast communication, and that bone matrix provides extracellular storage of miR-125b that is functionally active in bone resorption.

Osteoblast-derived vesicles induce a switch from bone-formation to bone-resorption in vivo

Article Open access 24 February 2022

RUFY4 deletion prevents pathological bone loss by blocking endo-lysosomal trafficking of osteoclasts

Article Open access 15 May 2024

Osteoclast-derived apoptotic bodies couple bone resorption and formation in bone remodeling

Article Open access 11 January 2021

Introduction

Cell-to-cell communication is pivotal for all multicellular organisms. Most cell types exchange information through soluble factors or direct interaction, but they also release extracellular vesicles (EVs) that can have an impact on neighboring or distant cells. The biological significance of EVs has been affirmed in numerous studies on intercellular communication that document the transfer of proteins, lipids, and nucleic acids; of these, microRNAs (miRNAs) have drawn much attention as EV cargos^1,2. miRNAs, ~22 nucleotides in length, constitute a class of non-coding RNAs and induce gene silencing by binding to target sites within the 3′UTR of targeted mRNAs, resulting in suppressing protein synthesis and/or mRNA degradation³. miRNAs have been shown to be involved in a wide range of biological processes such as cell cycle control⁴, developmental processes⁵, glucose homeostasis⁶, immune responses⁷, bone metabolism⁸, and so on.

In general, EVs are released into the extracellular fluids; however, matrix vesicles (MVs) budding from polarized mature osteoblasts accumulate in the unmineralized bone matrix (osteoid). MVs in the osteoid initiate calcium and phosphate crystal formation inside vesicles by utilizing the calcium channels, phosphate transporters, and enzyme activities required in calcium and phosphate transport and initial mineral formation. Calcium phosphate crystals thereafter grow, penetrate the lipid bilayer of MVs, and expand to mineralize bone matrix⁹. Advances in global analysis indicate that MVs share certain features in common with EVs^10,11, including the presence of miRNAs¹² and of numerous proteins (see http://bioinf.xmu.edu.cn/MVsCarta/), some of which are known regulators of osteoclast and osteoblast development (e.g., TNFRSF11B¹³, WNT5A¹⁴, SEMA4D¹⁵), but whether they are functionally active when carried as cargo is not yet known. We therefore tested the hypothesis that MVs play an important, previously undefined role in osteoclasts and osteoblasts beyond their known involvement in bone matrix mineralization. We report here that miR-125b is a MV cargo that accumulates in bone matrix where it inhibits osteoclastogenesis and bone resorption via downregulation of the transcriptional repressor PRDM1.

Results

MVs inhibit osteoclast formation in vitro

To address possible novel bone biological functions of MVs, we isolated MVs from the extracellular matrix (ECM) deposited by mouse osteoblastic MC3T3-E1 cells. The isolated vesicles fulfilled the expected morphological and biochemical criteria of MVs⁹ (Supplementary Fig. 1a–d). Treatment of mouse bone marrow macrophage (BMM) cultures with isolated MVs in the presence of CSF1 (M-CSF) and TNFSF11 (RANKL)^16,17,18 decreased formation of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs, i.e., osteoclasts) (Fig. 1a); no osteoclasts formed with or without MVs in the absence of RANKL (Fig. 1a). Consistent with the histochemical results, treatment with MVs also decreased the expression of osteoclast marker genes Nfatc1, a transcription factor necessary for osteoclastogenesis¹⁸, Dcstamp¹⁹ and Ctsk²⁰ (Fig. 1b) as well as resorption pit formation²¹ (Fig. 1c). Similar effects were observed in the mouse macrophage cell line, RAW-D (Supplementary Fig. 2a, b) with RANKL, in which an accompanying uptake of dye from labeled MVs to cells was also evident (Supplementary Fig. 2c). Treatment with MVs from rat and human primary osteoblast cultures (Supplementary Fig. 2d, e) confirmed the presence of anti-osteoclastogenic factor(s) in MVs across species. The RANKL-decoy receptor TNFRSF11B (osteoprotegerin (OPG)), which inhibits osteoclastogenesis^13,22, has been reported in MVs in the conditioned medium of vascular smooth muscle cells (http://bioinf.xmu.edu.cn/MVsCarta/). Contrary to smooth muscle cells, we did not detect OPG in our osteoblast-derived MVs (Supplementary Fig. 1c), suggesting that MVs inhibit osteoclast formation independently of the RANKL-OPG pathway. Although dye transfer occurred from labeled MVs to MC3T3-E1 cells (Supplementary Fig. 3a), MVs did not elicit significant effects on osteogenic differentiation and bone-like nodule formation in these (Supplementary Fig. 3b) or rat primary osteoblast (Supplementary Fig. 3c) cultures. The data suggest that MVs modulate osteoclastogenesis but not osteoblastogenesis in vitro.

**Fig. 1: MVs and miR-125b impair TRAP⁺ multinucleated cell (MNC) formation.**

miR-125b mimics the MV effects in vitro

Recently PCR array profiling has identified miRNAs in MVs isolated from rat chondrocyte cultures¹². We therefore used miRNA microarray analysis of osteoblastic (MC3T3-E1) MVs and identified 176 miRNAs (GSE140242 at NCBI GEO), 76 of which were common between mouse and human (Supplementary Data 2), with several good candidates for regulators of genes involved in osteoclast formation^{23,24,25,26,27} (Supplementary Table 1). Of these, miR-125b was more abundant in MVs than in the parent MC3T3-E1 cells from which they derived (Fig. 1d), primary human and rat osteoblasts (Fig. 1e) and RAW-D cells cultured with or without RANKL (Fig. 1f). Notably, however, treatment with MVs increased miR-125b levels in RAW-D cells (Fig. 1g). We then established a subclone of MC3T3-E1 cells with lower levels of miR-125b (Supplementary Fig. 4a) but normal osteogenic capacity (E1^low) (Supplementary Fig. 4b) to do a loss-of-function study. MVs from E1^low cells had no significant effect on TRAP⁺ MNC formation in RAW-D cells (Supplementary Fig. 4c). Meanwhile, transfection of miR-125b mimic (Fig. 1g) had higher efficacy than those with control miRNA against TRAP⁺ MNC formation (Fig. 1h) and associated gene expression (Nfatc1, Dcstamp, and Catsk) (Fig. 1i). miR-125b mimic (Supplementary Fig. 4d) did not affect osteogenesis in MC3T3-E1 or the mouse mesenchymal stem cell line ST2 models (Supplementary Fig. 4e, f). These data indicate that miR-125b participates in the inhibitory effect of MVs on osteoclastogenesis in vitro.

Transgenic mice have high bone mass and fewer osteoclasts

To determine whether miR-125b as MV cargo plays a functional role in bone in vivo, we generated transgenic (Tg) mouse lines (#5, #7, and #16; Supplementary Fig. 5a) expressing mmu-miR-125b-5p in osteoblasts by using human osteocalcin promoter²⁷ (Fig. 2a, b). Mice (males) of the three lines at 9- and 12-weeks of age exhibited identical phenotypes including high bone mass (Supplementary Fig. 5b); line #5 was used for further analyses. Figure 2b shows cell- and tissue-specific expression of miR-125b in Tg mice, which were born at normal Mendelian ratios and grew normally (Supplementary Fig. 5c). Tg femurs (12-week-old males) and vertebrae (L3 of 10-week-old females) exhibited higher bone mass than their corresponding wild-type (WT) mice (Fig. 2c), due to increased trabecular bone (12-week-old females, Fig. 2d); histological assessment of Tg tibiae (9- and 10-week-old female mice) also confirmed this event (Supplementary Fig. 6a–c). WT and Tg mice displayed equal numbers of alkaline phosphatase (ALP)-positive osteoblasts (Fig. 2e) and equal mineral apposition rates (MARs; calcein double-labeling) (Fig. 2f), indicating that bone formation was not affected by miR-125b overexpression in osteoblasts. However, the percentage of TRAP⁺ cell surface per trabecular bone surface was lower in Tg compared to WT mice (Fig. 2g). No difference in TRAP staining was seen in the zone of calcified cartilage and subchondral bone (Fig. 2h), which may reflect lower accumulation of miR-125b in bone at the chondro-osseous junction in Tg mice.

**Fig. 2: Transgenic (Tg) mice overexpressing miR-125b in osteoblasts exhibit a high bone mass phenotype.**

miR-125b targets Prdm1 in osteoclast precursors

To identify the mechanisms underlying MV-mediated impaired osteoclastogenesis, we analyzed Tg and WT bone and bone marrow populations ex vivo. No difference was observed in bone formation between Tg and WT bone marrow stromal cell cultures (Fig. 3a) or between Tg and WT calvaria cell cultures (Supplementary Fig. 7a). Similarly, no difference was seen between Tg and WT cellular and MV ALP activity (Supplementary Fig. 7b) or their ALPL and ANXA5 levels (Supplementary Fig. 7c). However, higher levels of miR-125b were present in Tg vs. WT MVs (Supplementary Fig. 7d) and in Tg vs. WT bone matrix (Fig. 3b). Given that miR-125b was not detected in conditioned media from either Tg or WT calvaria cell cultures (Supplementary Fig. 7d), these results suggest that miR-125b secreted from osteoblasts is mostly or all sequestered in the bone matrix via MVs.

**Fig. 3: miR-125b in bone matrix inhibits osteoclastogenesis by targeting *Prdm1*.**

Neither TRAP⁺ MNC formation (Fig. 3c) nor ability to resorb bone in vitro (Supplementary Fig. 7e) was different between Tg and WT BMM cell cultures. Similarly, and consistent with the view that osteoblast-secreted miR-125b is undetectable in conditioned medium but is sequestered in the bone matrix via MVs, osteoclast formation was the same in Tg and WT BMMs cocultured with either Tg or WT osteoblasts (calvaria cells forming osteoid-like nodules) (Supplementary Fig. 7f). FACS analysis revealed that CD117⁺/CD115⁺/CD11b^low osteoclast progenitors²⁸ (Fig. 3d), macrophages, hematopoietic stem cells, and B cells were comparable between the two strains, with a small but substantial reduction in T cells in Tg mice in comparison with those in WT mice (Supplementary Fig. 8). Taken together, these data suggest that miR-125b trapped in bone matrix inhibits osteoclastogenesis. Indeed, treatment of RWA-D cells with Tg MVs resulted in greater inhibition of osteoclast formation than that with WT MVs (Fig. 3e). When either Tg or WT BMMs were cultured on Tg vs. WT bones in the presence of RANKL and M-CSF, TRAP⁺ spots were less on Tg than WT bones (Fig. 3f). These results suggest that bone matrix miR-125b decreases osteoclastogenesis.

We then searched public databases to identify putative miR-125b target(s) (Supplementary Table 2). Of these, PR domain containing 1, with zinc finger domain (PRDM1), a transcriptional repressor of anti-osteoclastogenic factors¹⁶, was selectively downregulated in RAW-D cells transfected with miR-125b mimic (Supplementary Fig. 9) or treated with MVs (Fig. 3g). Luciferase activity was reduced in RAW-D cells co-transfected with miR-125b mimic and Prdm1 3′UTR reporter vector, but not with miR-125b mimic and Prdm1 mutant 3′UTR reporter vector²⁹ (Fig. 3h). Further, the miR-125b mimic decreased levels of Prdm1 in RAW-D cells and concomitantly increased mRNA (Fig. 3i) and protein (Supplementary Fig. 10) levels of two known downstream targets of PRDM1 that are inhibitors of osteoclastogenesis, interferon regulatory factor 8 (Irf8)³⁰ and v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (Mafb)³¹, but not of a third potential inhibitor, B-cell lymphoma 6 (Bcl6)¹⁶. The latter may reflect the fact that we assessed at day 4 and may have missed later events in osteoclastogenesis, as it is known that Bcl6 is downregulated at a later stage of osteoclastogenesis (by 8 days)¹⁶ than either Irf8³⁰ or Mafb³¹(by 24 h). Nevertheless, our results strongly suggest that miR-125b suppresses osteoclast formation via downregulation of PRDM1.

miR-125b protects bone loss in mouse disease models

To determine whether MV-based transfer of miR-125b to bone matrix represents a potential therapeutic target, we ovariectomized (OVX) 8-week-old female mice, as a model of postmenopausal osteoporosis³². Four weeks post-OVX, body weight was increased (Fig. 4a) and uteri were hypoplastic (Fig. 4b) in both WT and Tg mice, indicating effective estrogen depletion. However, OVX-induced trabecular bone loss was lower in Tg compared to WT femora (Fig. 4c–e). Trabecular bone loss was also markedly blunted in 10-week-old male Tg vs. WT mice subjected to sciatic neurectomy (NX), a model of disuse or immobilization-induced osteoporosis³³ (Supplementary Fig. 11a, b). Thus, overexpression of miR-125b in osteoblasts confers resistance to bone loss in mouse osteoporosis models. Finally, to confirm that miR-125b inhibits osteoclastogenesis in vivo, we used subcutaneous injections of bacterial lipopolysaccharides (LPSs) over the calvariae to increase osteoclastogenesis and induce osteolysis³⁰. Whole-mount staining showed that LPS-induced TRAP staining was attenuated, when miR-125b mimic was co-injected subcutaneously (Fig. 4f). These results indicate that miR-125b can inhibit bone resorption in at least some pathologic conditions. Taken together, our data identify miR-125b accumulated in bone matrix as a player in bone metabolism via osteoblast–osteoclast coupling and as a potential therapeutic target to abrogate bone loss.

**Fig. 4: miR-125b protects mice from pathological bone loss.**

Discussion

MVs budding from osteoblasts are known to accumulate in osteoid and play a crucial role in the initial steps of bone mineralization⁹. However, potential but undefined roles of MVs in bone metabolism have been postulated recently, based on comprehensive analyses of proteins in MVs^10,11. Together with other recent findings of miRNAs as functional EV cargos^1,2, these prompted us to test for functional roles of MVs in bone. We report here that miRNAs in osteoblasts are transported to bone matrix by MVs. Of these, miR-125b is selectively and abundantly incorporated into MVs and stored in bone matrix. During bone resorption, miR-125b is released and targets PRDM1, a transcriptional repressor of anti-osteoclastogenic factors^16,17 in osteoclast precursors. Tg mice overexpressing miR-125b in osteoblasts exhibit increased miR-125b levels in MVs and bone matrix, resulting in decreased osteoclast numbers and increased bone mass. Overexpressing miR-125b in osteoblasts also abrogates the bone loss associated with estrogen deficiency and immobilization in mice, consistent with the suppression of LPS-induced osteoclast formation and osteolysis by injecting mice with miR-125b mimic.

That osteoblasts secrete EVs and/or MVs with active biological molecules as cargo is not in itself surprising. Indeed, a list of numerous cargo proteins is available at http://bioinf.xmu.edu.cn/MVsCarta/, but little is known about whether MV cargo molecules accumulate in bone matrix, or have a substantial impact on bone metabolism or turnover. Treatment of mouse BMMs with EVs isolated from conditioned media of primary mouse osteoblast cultures has been shown to promote survival of osteoclasts by the action of the cargo RANKL³⁴. However, we found that MVs do not mimic this effect, but rather inhibit formation of osteoclasts and resorption pits, suggesting that anti-osteoclastogenic factor(s) accumulate in MVs and are transported to bone matrix via MVs but not EVs. Recently, MVs isolated from rat growth plate chondrocytes were reported to be selectively enriched in certain miRNAs, including miR-122-5p, miR-142-3p, miR-223-3p, and miR-451-5p¹². We then focused our attention on miRNAs as MV cargos. Interestingly, the enrichment profile we identified in mouse, rat, and human osteoblast MVs is distinctly different from that in rat chondrocytes¹², suggesting that MVs from at least certain types of chondrocytes exhibit a functionally distinct role, from osteoblast MVs.

By in silico analyses, qRT-PCR screens, and selection of candidate miRNAs more abundant in osteoblasts and MVs than osteoclasts or their precursor cells (BMMs and RAW-D cells), we identified miR-125b for further study. We confirmed that the MV cargo miR-125b regulates osteoclastogenesis but not osteoblastogenesis by gain- and loss-of function experiments in vitro. While overexpression of miR-125b in osteoblasts clearly decreases osteoclastogenesis, we found no evidence for miR-125b regulation of osteoblast differentiation or bone formation in vivo. Of previous studies assessing miR-125b in osteoblast differentiation, only two have reported a regulatory role for miR-125b in osteogenesis, one with human bone marrow stromal cells, which are from a multipotent stem cell-like population differentiated under the influence of a medium whose constituents were undisclosed or transplanted on demineralized bone matrix³⁵, and the other with ST2 stem-like cells in the presence of BMP-4³⁶. We have found no detectable effect of miR-125b on the MC3T3-E1 model cultured under osteogenic conditions or ST2 cells undergoing osteogenesis in vitro in the absence of BMP-4. We also found no effect on osteogenesis when we overexpressed miR-125b in post-mitotic mature osteoblasts ex vivo and in vivo. It is not surprising that miR-125b effects are different in different conditions in vitro and in vivo, given the likelihood of extracellular signal- and/or differentiation stage-specific miR-125b target gene expression profiles in these different models. It is also possible that the ability to detect effects of exogenously added miR-125b on osteoblast development in vitro and ex vivo/in vivo are abrogated by the already abundant expression of miR-125b in these cells.

It is known that circulating miRNAs, whether within EVs or not, are mostly associated with RNA-induced silencing complexes (RISCs)³⁷. The presence of miRNAs in various body fluids is now well-established³⁸, but we show that the biologically active miR-125b within RISC accumulates and is retained in the extracellular bone matrix. Of established genes involved in osteoclastogenesis, we confirmed that Prdm1 is a target of miR-125b. PRDM1 was originally isolated in human osteosarcoma cell lines³⁹ and acts as a transcriptional repressor. In addition to osteoclastogenesis^16,17, PRDM1 is involved in plasma cell fate determination⁴⁰, and forced expression of miR-125b decreases PRDM1 levels in the human lymphoma cell line PC-K8 via its binding activity to Prdm1 3′UTR⁴¹. Of identified targets of miR-125b, physiological silencing of miR-125b is required in mouse granulocytic differentiation⁴² and B-cell development⁴³ in vitro via the targeting of Jund and S1pr1, respectively. The other established target of miR-125b, Lyn28, is involved in myeloid vs. B-cell fate determination in mouse hematopoietic stem cell cultures⁴⁴. However, FACS analysis showed no significant differences in bone marrow cells except for a small but substantial reduction in T cells in Tg vs. WT mice. Together the data suggest that the accumulation of MVs in bone matrix creates the conditions by which osteoblast-derived miR-125b regulates osteoclastogenesis. During bone mineralization, calcium phosphate crystals grow in and break through MVs⁹, resulting in miR-125b capture in mineralizing bone. As is true with other active proteins embedded in bone matrix, e.g., TGF-β1 (ref. ⁴⁵) during bone resorption, miR-125b would be released allowing its anti-osteoclastogenic activity to be manifest. This also predicts that there is a certain threshold of bone resorption required to achieve levels of miR-125b for its anti-osteoclastogenic effects.

Antiresorptive agents such as bisphosphonates and anti-RANKL antibodies have been used for many years, especially in the treatment of patients with osteoporosis and bone metastasis. These agents block bone resorption, resulting in suppression of bone turnover^46,47. While the clinical benefits of anti-resorptive agents are clear, reduced bone turnover can have deleterious effects, e.g., medication-related osteonecrosis of the jaws, leading to ongoing efforts to identify additional approaches to maintaining and improving bone mass in a variety of conditions. It is interesting that overexpression of miR-125b in osteoblasts has a protective effect against both OVX- and NX-induced bone loss in our Tg mice and miR-125b rescues LPS-dependent osteolysis. Taken together, osteoblast–osteoclast communication via the MV cargo miR-125b represents a potential therapeutic target for bone loss (Fig. 5). As a corollary to this, future research directions must also include more detailed dissection of physiological role(s) of miR-125b in bone, as well as the mechanism(s) underlying selective accumulation of miR-125b in MVs, retention of miR-125b activity in mineralized bone overtime and delivery-uptake of miR-125b by osteoclast precursors and possibly other cells (e.g., T-cells) in the bone microenvironment.

**Fig. 5: Schematic diagram of osteoblast–osteoclast communication by miR-125b.**

Methods

Animals

C57BL/6J and ddY mice and timed-pregnant Wistar rats were obtained from CLEA Japan or Charles River Laboratories Japan. Tg mice overexpressing miR-125b in osteoblasts were developed on the C57BL/6J background. Animal use and procedures were approved by the Institutional Animal Care and Use Committee at the Central Institute for Experimental Animals and the Committee of Animal Experimentation at Hiroshima University (#A14-078).

Vector construction

A 422-base-pair mouse genomic sequence including pre-miRNA-125b-1 and rabbit βglobin intron and poly A were amplified by PCR from mouse and rabbit genomic DNA, respectively, and cloned into pBlueScript II SK(+) (miR-125b vector, UNITECH)⁴⁸. A 4072-base-pair human osteocalcin promoter²⁷ was amplified from human BAC clone (RP11-964F7). The human osteocalcin promoter fragment was inserted into the NotI/SpeI sites of the miR-125b vector, and the 5690-base-pair NotI/SalI fragment was isolated, purified, and used for microinjection. Tg mice were identified by PCR. Primer pairs are described in Supplementary Table 3.

Microcomputed tomography (µCT)

Bones were fixed in 4% paraformaldehyde (PFA) in PBS at 4 °C overnight and stored in 70% ethanol. Samples were imaged using Skyscan 1176 at an X-ray energy of 40 kV with a voxel size of 17.5 µm on each side and an exposure time of 230 ms (Bruker microCT). Image reconstruction and bone morphometry (proximal tibiae) were performed using NRecon and CTvox software, respectively (Bruker microCT).

Calcein double-labeling and plastic sections

Calcein (100 µg/kg body weight) was administered intraperitoneally twice (at a 6-day interval) to 10-week-old male mice. Femurs were dissected 2 days after the second administration, fixed in 4% PFA in PBS and embedded in Epon by standard techniques, and the MAR was determined on plastic semi-thin sections studied under fluorescence microscopy⁴⁹.

Histology

PFA-fixed bones were decalcified with 10% EDTA in PBS at 4 °C for a week and embedded in paraffin by standard techniques. Deparaffinized sections (4 µm thick) were stained with TRAP to evaluate osteoclasts^16,17,18. To determine osteoblasts by ALP staining, sections were rinsed with Tris-buffered saline (20 mM Tris-HCl, 137 mM NaCl; pH 7.6) containing 0.025% Triton X-100 and incubated with Protein Block (Dako), followed by incubation with anti-ALPL antibody (×200, Proteintech) in Can Get Signal® Solution A (Toyobo) at 4 °C overnight. Alexa Fluor® 594-conjugated antibody (Thermo Fisher Scientific) was used as the secondary antibody. Fluoro-KEEPER with DAPI was used for nuclear staining.

Analysis of osteoclast progenitors

Bone marrow cells were prepared from femurs and tibiae of 10-week-old male mice. Cells were passed through a cell strainer (70 µm; Falcon®), centrifuged, and the resultant cell pellets were resuspended in ACK lysis buffer (0.15 M NH₄Cl, 0.01 M KHCO₃, and 1 mM Na₂ EDTA; pH7.4) (hemolysis). After gentle agitation for 2 min, cell suspensions were centrifuged and rinsed. Resuspended cells (4 × 10⁵ cells in 100 μL of 0.5% BSA in PBS) were treated with TruStain fcX for 5 min on ice, followed by incubation with labeled antibodies or isotype controls for 60 min at 4 °C. Cells were then treated with 1 mM EDTA and 2% BSA in PBS, centrifuged and resuspended with 0.5% BSA in PBS. Osteoclast progenitors were determined by FACS (LSRFortessa X-20, BD Biosciences) using CD115-Alexa Fluor 488, CD11b-APC, and CD117-PE (BioLegend)²⁸ (Supplementary Table 4).

Ovariectomy (OVX)

Eight-week-old female mice were overiectomized or sham-operated³², and samples were collected 4 weeks later.

LPS-induced osteolysis in vivo

LPS (Escherichia coli, 026:B65; Lot #025M4088V; Sigma-Aldrich) was administered subcutaneously over the calvariae³⁰ of 8-week-old male ddY mice at days 0, 1, 3, and 5 (3.75 mg/kg/day). A miR-125b mimic or its scrambled negative control (7 nmol each, Ambion) in AteloGene® (Koken) was injected subcutaneously into the region close to the LPS-treated sites 12 h before day 0 and at days 2 and 4. Calvariae were dissected at day 6 and fixed in 95% ethanol and 5% acetic acid for whole-mount TRAP staining.

Cell cultures

MC3T3-E1 cells and ST2 cells were purchased from the RIKEN BRC. Human osteoblastic cells were kindly provided by DV Biologics. Mouse and rat calvaria cells were obtained from newborn C57BL/6 mice (around 3 days old) and 21-day-old fetal Wistar rats, respectively⁵⁰. Briefly, calvariae were aseptically dissected and sequentially digested five times with type I collagenase (Sigma-Aldrich) for 10–20 min. Cell fractions, except for the first one, were separately cultured in α-MEM containing 10% FBS (Corning) and pooled the next day. We also established the MC3T3-E1 cell subclone (E1^low) that expresses miR-125b at low levels by limiting dilution cloning⁵¹. To determine osteoblastogenesis, cells were plated at 3000 cells/cm² in the above medium additionally supplemented with 50 µg/mL ascorbic acid (osteogenic medium) with or without 10 mM β-glycerophosphate (βGP) for 2–3 weeks. Cells were fixed with 4% PFA in PBS and subjected to ALP and von Kossa staining. Image J 1.48 software (NIH) was used to measure ALP- or ALP/von Kossa-positive (ALP⁺/von Kossa⁺) areas. ALP⁺/von Kossa⁺ nodules were counted under a microscope.

Bone marrow cells from 9–12-week-old male mice were hemolyzed as above and cultured at 500,000 cells/cm² in non-adherent cell culture dishes with α-MEM supplemented with 10% FBS and 100 ng/mL M-CSF (R&D Systems) for 2 days. After removing non-adherent cells by washing with PBS, BMMs were collected using Cellstripper™ (Corning), passaged one time, and replated at 8000–20,000 cells/cm² and cultured with 50 ng/mL RANKL (Oriental Yeast) and 50 ng/mL M-CSF for 4–5 days^16,18. RAW-D cells were plated at 2000 cells/cm² in the presence or absence of 50 or 100 ng/mL RANKL for 4 days²⁰. TRAP-positive multinuclear cells (TRAP⁺ MNCs; five nuclei or more) were regarded as osteoclasts. In some resorption assays, Tg and WT BMMs (9500 cells/cm²) were cultured on calvarial bone chips (6 mm × 6 mm) for 6 days, followed by fixation with 4% PFA in PBS, TRAP staining, and Image J analysis. Calvarial bone chips were collected from either Tg or WT newborn mice and preserved in ice-cold methanol for a few days at −20 °C. All cells were cultured at 37 °C in a humidified atmosphere with 5% CO₂ with medium changes every second or third day, unless otherwise specified.

Resorption pit formation assay

BMMs at 100,000–280,000 cells on dentin slices (Wako) or bovine cortical bone slices were grown in α-MEM supplemented with 10% FCS, with 50 ng/mL M-CSF and 50 ng/mL RANKL up to 7–14 days. Dentin/bone slices were rinsed with ammonia water, stained with hematoxylin or toluidine blue²¹ and resorption pit areas measured by Image J.

Isolation of MVs

MVs were isolated from the ECM deposited by osteoblasts⁵². Briefly, MC3T3-E1 cells, primary calvaria cells, and human osteoblastic cells were grown at 3000 cells/cm² in osteogenic medium. To confirm the formation of bone-like nodules, βGP was added to parallel cultures. When the ECM (osteoid-like nodules) formed (−3 weeks), cultures without βGP were treated with 500 units/mL collagenase (Sigma-Aldrich) at 37 °C for 45 min under static conditions and for 15 min with shaking. Samples were then centrifuged at 20,000 × g for 20 min, and pellets were subjected to protein and total RNA extraction as cell extracts. Supernatants were centrifuged at 100,000 × g for 60 min, and the resultant pellets were resuspended in 100 mM mannitol in 10 mM HEPES (pH 7.5), followed by centrifugation at 350,000 × g for 30 min. Finally, MV pellets were resuspended in PBS and aliquots (2 μg protein/μL stock solution) were stored in liquid nitrogen until use. Two micrograms of protein/mL or less of MVs were used for bioassays.

BCA protein assay

Protein levels in lysates of MVs or cells (Cell-LyEX MP, TOYO B-Net) including phosphatase inhibitors) were determined using colorimetric detection according to the manufacturer’s instructions (Pierce™ BCA protein assay kit, Thermo Fisher Scientific).

Comprehensive analysis of miRNAs in MVs

miRNAs in MVs from MC3T3-E1 cells were extracted three times independently using a mirVana™ miRNA isolation kit, according to the manufacturer’s instructions (Ambion). Probe labeling (using 100 ng of total RNA) and hybridization were performed using a miRNA Complete Labeling and Hyb kit and a SurePrint G3 mouse miRNA microarray rel.17 kit, respectively (Agilent Technologies). miRNA profiling for three MVs was analyzed using an Agilent G2539A microarray scanner and analysis software GeneSpring GX (version 12.5.0, Agilent Technologies). Of miRNAs identified, we focused on those common to humans and mice, and predicted targets were searched using public databases (miRTarBase: http://mirtarbase.mbc.nctu.edu.tw; miRDB: http://mirdb.org/miRDB/; RNA22: https://cm.jefferson.edu/rna22v2/; and TargetScanHuman 6.2: http://www.targetscan.org/).

AGO2 immunoprecipitation of bones

The osteocyte isolation method⁵³ with slight modification was used to obtain miRNAs from bone matrices. Briefly, calvariae from 8–15-week-old male C57BL/6 mice were cut into small pieces (2 × 2 mm), washed, and digested with 300 U/mL collagenase (type I, Sigma-Aldrich) in isolation buffer (70 mM NaCl, 10 mM NaHCO₃, 60 mM sorbitol, 30 mM KCl, 3 mM K₂HPO₄, 1 mM CaCl₂, 1 mg/mL BSA, and 5 mg/mL glucose in 25 mM HEPES; pH7.4) at 37 °C for 20 min with shaking. Undigested bone pieces were then stirred two times with 10% EDTA in PBS at 37 °C for 20 min and 30 min. All digestion fractions were divided into cell pellets and bone matrix extracts by centrifugation. miRNAs were trapped by antibodies against AGO2 as part of the RISC³⁷. Aliquots of cell pellets lysed with lysis buffer and bone matrix extracts were incubated with anti-AGO2 mouse antibody-conjugated magnetic beads at 4 °C overnight according to the manufacturer’s instructions (MagCapture miRNA kit, Wako). Mouse IgG (Santa Cruz Biotechnology)-conjugated Dynabeads Protein G (Life Technologies) were used as control. After washing, immunoprecipitates with magnetic beads were eluted and processed for RNA extraction according to the manufacturer’s instructions.

miR-125b mimic transfection

RAW-D cells at 2000–3000 cells/cm² were grown overnight and transfected with miR-125b mimic or its scrambled negative control (10 nM each) using RNAiMAX reagent (Life Technologies) or HiperFect Transfection Reagent (Qiagen), according to the manufacturers’ instructions. After 3 h, a small amount of fresh medium including RANKL (final 50 ng/mL) was added to cultures, and cells were maintained for an additional few days.

Prdm1 3ʹUTR luciferase reporter vector and luciferase assay

The 3′UTR of Prdm1 (2693-3145 in NCBI accession #: NM_007548.3) was amplified from genomic DNA of RAW-D cells. The amplified 3′UTR was cloned into the SpeI and HindIII sites of pMIR-REPORT (Invitrogen). The mutant 3′UTR²⁹ was generated using primer sets and cloned as described above. Primer sets are shown in Supplementary Table 3. RAW-D cells were grown at 25,000 cells/cm² overnight and then co-transfected with reporter plasmid (80 ng) and pGL44.74[hRluc/TK] vector (40 ng; Promega; Madison, WI) using Attractene Transfection Reagent (Qiagen), according to the manufacturer’s instructions. Twenty-four hours later, miR-125b mimic or negative control (10 nM each, Ambion) was introduced into cells as described above. Cells were maintained for an additional 36 h and then lysed in passive lysis buffer (Promega). Measurements were performed using the Dual-luciferase® reporter assay system (Promega).

PCR analysis

Genomic DNA was extracted and the transgene was determined using KOD FX Neo (Toyobo) with specific primer sets. miRNAs in conditioned media were isolated by using a miRNeasy Serum/Plasma Advanced kit (Qiagen). Total RNA was isolated from cells using TriPure isolation reagent (Roche Diagnostics), and reverse-transcribed using ReverTra Ace® (Toyobo). For miRNAs, TaqMan® microRNA assays (Applied Biosystems), and their corresponding primer sets, including U6 (cells and MVs) and miR-16 (bone matrix) as internal controls, were used according to the manufacturers’ instructions. For mRNAs, Rpl32 served as internal control, and qPCR amplification was conducted using Fast SYBR® green master mix (Applied Biosystems). The sequences of primer sets are shown in Supplementary Table 3.

Statistics and reproducibility

Data are expressed as mean ± SD. Non-numerical data are shown as representative results of three independent experiments. Statistical differences were evaluated using either one-way or two-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison (multiple groups) or Student’s t-test (two groups). A P-value < 0.05 was considered statistically significant.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The majority of the data supporting the findings of this study are included in this published article. Additionally, raw data are available from the corresponding author on reasonable request. The source data underlying plots are presented in Supplementary Data 1. The miRNA microarray data are deposited into NCBI GEO (accession number: GSE140242). miRNAs identified in MVs are shown in Supplementary Data 2.

References

Tkach, M. & Théry, C. Communication by extracellular vesicles: where we are and where we need to go. Cell 164, 1226–1232 (2016).
Article CAS PubMed Google Scholar
Budnik, V., Ruiz-Cañada, C. & Wendler, F. Extracellular vesicles round off communication in the nervous system. Nat. Rev. Neurosci. 17, 160–172 (2016).
Article CAS PubMed PubMed Central Google Scholar
Lin, S. & Gregory, R. I. MicroRNA biogenesis pathway in cancer. Nat. Rev. Cancer 15, 321–333 (2015).
Article CAS PubMed PubMed Central Google Scholar
Huang, W. et al. Loss of microRNA-128 promotes cardiomyocyte proliferation and heart regeneration. Nat. Commun. 9, https://doi.org/10.1038/s41467-018-03019-z (2018).
Choi, Y. et al. Deficiency of microRNA miR-34a expands cell fate potential in pluripotent stem cells. Science 355, eaag1927 (2017).
Article PubMed PubMed Central CAS Google Scholar
Zhuo, S. et al. MicroRNA451 negatively regulates hepatic glucose production and glucose homeostasis by targeting glycerol kinase-mediated gluconeogenesis. Diabetes 65, 3276–3288 (2016).
Article CAS PubMed Google Scholar
KIlIç, A. et al. A systems immunology approach identifies the collective impact of 5 miRs in Th2 inflammation. JCI Insight 3, e97503 (2018).
Article PubMed Central Google Scholar
Li, D. et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun. 7, https://doi.org/10.1038/ncomms10872 (2016).
Hasegawa, T. Ultrastructure and biological function of matrix vesicles in bone mineralization. Histochem. Cell Biol. 149, 289–304 (2018).
Article CAS PubMed Google Scholar
Shapiro, I. M., Landis, W. J. & Risbud, M. V. Matrix vesicles: are they anchored exosomes? Bone 79, 29–36 (2015).
Article CAS PubMed PubMed Central Google Scholar
Cui, L., Houston, D. A., Farquharson, C. & MacRae, V. E. Characterization of matrix vesicles in skeletal and soft tissue mineralization. Bone 87, 147–158 (2016).
Article CAS PubMed Google Scholar
Lin, Z. et al. Selective enrichment of microRNAs in extracellular matrix vesicles produced by growth plate chondrocytes. Bone 88, 47–55 (2016).
Article CAS PubMed PubMed Central Google Scholar
Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597–3602 (1998).
Article CAS PubMed PubMed Central Google Scholar
Maeda, K. et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat. Med. 18, 405–412 (2012).
Article CAS PubMed Google Scholar
Negishi-Koga, T. et al. Suppression of bone formation by osteoclastic expression of semaphoring 4D. Nat. Med. 17, 1473–1480 (2011).
Article CAS PubMed Google Scholar
Miyauchi, Y. et al. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J. Exp. Med. 207, 751–762 (2010).
Article CAS PubMed PubMed Central Google Scholar
Nishikawa, K. et al. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc. Natl Acad. Sci. USA 107, 3117–3122 (2010).
Article CAS PubMed PubMed Central Google Scholar
Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889–901 (2002).
Article CAS PubMed Google Scholar
Kukita, T. et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J. Exp. Med. 200, 941–946 (2004).
Article CAS PubMed PubMed Central Google Scholar
Li, C. Y. et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J. Bone Miner. Res. 21, 865–875 (2006).
Article CAS PubMed Google Scholar
Merrild, D. M. et al. Pit- and trench-forming osteoclasts: a distinction that matters. Bone Res. 3, 15032 (2015).
Article CAS PubMed PubMed Central Google Scholar
Lüthy, R. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309–319 (1997).
Article PubMed Google Scholar
Sugatani, T., Vacher, J. & Hruska, K. A. A microRNA expression signature of osteoclastogenesis. Blood 117, 3648–3657 (2011).
Article CAS PubMed PubMed Central Google Scholar
Zhang, P. X. et al. Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation. Nat. Commun. 6, https://doi.org/10.1038/ncomms7221 (2015).
Rajaram, M. V. et al. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. Proc. Natl Acad. Sci. USA 108, 17408–17413 (2011).
Article CAS PubMed PubMed Central Google Scholar
Banerjee, S. et al. MicroRNA let-7c regulates macrophage polarization. J. Immunol. 190, 6542–6549 (2013).
Article CAS PubMed Google Scholar
Kesterson, R. A., Stanley, L., DeMayo, F., Finegold, M. & Pike, J. W. The human osteocalcin promoter directs bone-specific vitamin D-regulatable gene expression in transgenic mice. Mol. Endocrinol. 7, 462–467 (1993).
CAS PubMed Google Scholar
Kim, H. et al. Tmem64 modulates calcium signaling during RANKL-mediated osteoclast differentiation. Cell Metab. 17, 249–260 (2013).
Article CAS PubMed PubMed Central Google Scholar
White, C. A. et al. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J. Immunol. 193, 5933–5950 (2014).
Article CAS PubMed Google Scholar
Zhao, B. et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med. 15, 1066–1071 (2009).
Article CAS PubMed PubMed Central Google Scholar
Kim, K. et al. MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 109, 3253–3259 (2007).
Article CAS PubMed Google Scholar
Xie, Z. et al. A novel diterpenoid suppresses osteoclastogenesis and promotes osteogenesis by inhibiting Ifrd1-mediated and I∣B〈-mediated p65 nuclear translocation. J. Bone Miner. Res. 33, 667–678 (2018).
Article CAS PubMed Google Scholar
Moriya, S. et al. Cathepsin K deficiency suppresses disuse-induced bone loss. J. Cell Physiol. 231, 1163–1170 (2016).
Article CAS PubMed Google Scholar
Cappariello, A. et al. Osteoblast-derived extracellular vesicles are biological tools for the delivery of active molecules to bone. J. Bone Miner. Res. 33, 517–533 (2018).
Article CAS PubMed Google Scholar
Wang, H. et al. MiR-125b regulates the osteogenic differentiation of human mesenchymal stem cells by targeting BMPR1b. Cell Physiol. Biochem. 41, 530–542 (2017).
Article CAS PubMed Google Scholar
Mizuno, Y. et al. miR-125b inhibits osteoblastic differentiation by down-regulation of cell proliferation. Biochem. Biophys. Res. Commun. 368, 267–272 (2008).
Article CAS PubMed Google Scholar
Arroyo, J. D. et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA 108, 5003–5008 (2011).
Article CAS PubMed PubMed Central Google Scholar
Jessica, A. et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 56, 1733–1741 (2010).
Article CAS Google Scholar
Keller, A. D. & Maniatis, T. Identification and characterization of a novel repressor of β-interferon gene expression. Genes Dev. 5, 868–879 (1991).
Article CAS PubMed Google Scholar
Angelin-Duclos, C., Cattoretti, G., Lin, K. I. & Calame, K. Commitment of B lymphocytes to plasma cell fate is associated with Blimp-1 expression in vivo. J. Immunol. 165, 5462–5471 (2000).
Article CAS PubMed Google Scholar
Malumbres, R. et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 113, 3754–3764 (2009).
Article CAS PubMed PubMed Central Google Scholar
Surdziel, E. et al. Enforced expression of miR-125b affects myelopoiesis by targeting multiple signaling pathways. Blood 117, 4338–4348 (2011).
Article CAS PubMed Google Scholar
Li, G. et al. Epigenetic silencing of miR-125b is required for normal B-cell development. Blood 131, 1920–1930 (2018).
Article CAS PubMed PubMed Central Google Scholar
Chaudhuri, A. A. et al. Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. Proc. Natl Acad. Sci. USA 109, 4233–4238 (2012).
Article CAS PubMed PubMed Central Google Scholar
Tang, Y. et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757–766 (2009).
Article CAS PubMed PubMed Central Google Scholar
McClung, M. R. et al. Denosmab in postmenoposal women with low bone mineral density. N. Engl. J. Med. 354, 821–831 (2006).
Article CAS PubMed Google Scholar
Dore, R. K. et al. Effects of denosmab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann. Rheum. Dis. 69, 872–875 (2010).
Article CAS PubMed Google Scholar
Enomoto, Y. et al. Eμ/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia 25, 1849–1856 (2011).
Article CAS PubMed Google Scholar
Hayashibara, T. et al. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J. Bone Miner. Res. 19, 455–462 (2004).
Article CAS PubMed Google Scholar
Bellows, C. G., Aubin, J. E., Heersche, J. N. & Antosz, M. E. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif. Tissue Int. 38, 143–154 (1986).
Article CAS PubMed Google Scholar
Wang, D. et al. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J. Bone Miner. Res. 14, 893–903 (1999).
Article CAS PubMed Google Scholar
Montessuit, C., Bonjour, J. P. & Caverzasio, J. Expression and regulation of Na-dependent P(i) transport in matrix vesicles produced by osteoblast-like cells. J. Bone Miner. Res. 10, 625–631 (1995).
Article CAS PubMed Google Scholar
Stern, A. R. et al. Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice. Biotechniques 52, 361–373 (2012).
CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

We thank S. Hiyama, M. Okumura, and A. Tomiyama for technical assistance. We also appreciate J. E. Aubin for helpful discussions and comments on the manuscript. We thank T. Kukita for the gift of RAW-D cells. T.M. and Y.T. were supported in part by MEXT KAKENHI (JP16K11443, T.M.; JP26861548, Y.T.). Y.Y. was supported by MEXT KAKENHI (JP18K19647), the Raffinee International Foundation and the Ono Pharmaceutical Foundation.

Author information

Hirotaka Yoshioka
Present address: Department of Anatomy, School of Medicine, International University of Health and Welfare, 4-3 Kozunomori, Narita, 286-8686, Japan
Yuichiro Takei
Present address: Department of Nutrition, Faculty of Nutrition, University of Kochi, 2751-1 Ike, Kochi, 781-8515, Japan

Authors and Affiliations

Department of Calcified Tissue Biology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan
Tomoko Minamizaki, Yuko Nakao, Yasumasa Irie, Faisal Ahmed, Shota Itoh, Nushrat Sarmin, Hirotaka Yoshioka, Chise Fujimoto, Yuichiro Takei & Yuji Yoshiko
Department of Orthodontics and Craniofacial Developmental Biology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan
Yuko Nakao, Shota Itoh & Kotaro Tanimoto
Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan
Yasumasa Irie & Katsuyuki Kozai
Natural Science Center of Basic Research and Development, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan
Asako Nobukiyo & Yusuke Sotomaru
Medical Genome Center, National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu, 474-8551, Japan
Shumpei Niida
Department of Animal Science, Graduate School of Science and Technology, Niigata University, 2-8050 Ikarashi, Nishi-ku, Niigata, 950-2181, Japan
Toshie Sugiyama
CNRS ERL 6001/ INSERM U1232, Institut de Cancérologie de l’Quest, 44805, Saint-Herblain, France
Edith Bonnelye

Authors

Tomoko Minamizaki
View author publications
You can also search for this author in PubMed Google Scholar
Yuko Nakao
View author publications
You can also search for this author in PubMed Google Scholar
Yasumasa Irie
View author publications
You can also search for this author in PubMed Google Scholar
Faisal Ahmed
View author publications
You can also search for this author in PubMed Google Scholar
Shota Itoh
View author publications
You can also search for this author in PubMed Google Scholar
Nushrat Sarmin
View author publications
You can also search for this author in PubMed Google Scholar
Hirotaka Yoshioka
View author publications
You can also search for this author in PubMed Google Scholar
Asako Nobukiyo
View author publications
You can also search for this author in PubMed Google Scholar
Chise Fujimoto
View author publications
You can also search for this author in PubMed Google Scholar
Shumpei Niida
View author publications
You can also search for this author in PubMed Google Scholar
Yusuke Sotomaru
View author publications
You can also search for this author in PubMed Google Scholar
Kotaro Tanimoto
View author publications
You can also search for this author in PubMed Google Scholar
Katsuyuki Kozai
View author publications
You can also search for this author in PubMed Google Scholar
Toshie Sugiyama
View author publications
You can also search for this author in PubMed Google Scholar
Edith Bonnelye
View author publications
You can also search for this author in PubMed Google Scholar
Yuichiro Takei
View author publications
You can also search for this author in PubMed Google Scholar
Yuji Yoshiko
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

T.M., Y.N. and Y.T. prepared the manuscript. T.M. conducted the in vivo and ex vivo experiments, and Y.N., T.S., and Y.T. directed the in vitro analyses. Y.N., N.S. and C.F. purified and characterized MVs and screened miRNAs. Y.I. screened the target genes and performed miRNA expression analysis. F.A. and S.I. contributed to bone morphometric analyses. A.N. and Y.S. generated Tg mice. S.N. and H.Y. supported the microarray analysis. K.T. and K.K. supported data analyses. E.B. contributed to review and editing. Y.Y. directed the project and helped to prepare the manuscript. All authors discussed the results.

Corresponding author

Correspondence to Yuji Yoshiko.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Description of Additional Supplementary Files

Supplementary Data 1

Supplementary Data 2

Reporting Summary

Peer Review File

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Minamizaki, T., Nakao, Y., Irie, Y. et al. The matrix vesicle cargo miR-125b accumulates in the bone matrix, inhibiting bone resorption in mice. Commun Biol 3, 30 (2020). https://doi.org/10.1038/s42003-020-0754-2

Download citation

Received: 04 September 2018
Accepted: 17 December 2019
Published: 16 January 2020
DOI: https://doi.org/10.1038/s42003-020-0754-2

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.